Correlating excipient effects on conformational and storage stability of an IgG1 monoclonal antibody with local dynamics as measured by hydrogen/deuterium-exchange mass spectrometry

Journal of Pharmaceutical Sciences

Volumn 102, Issue 7, 2013, Pages 2136-2151

  Manikwar, Prakash ^a   Majumdar, Ranajoy ^a   Hickey, John M ^a   Thakkar, Santosh V ^a,c   Samra, Hardeep S ^b   Sathish, Hasige A ^b   Bishop, Steven M ^b   Middaugh, C Russell ^a   Weis, David D ^a   Volkin, David B ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b MEDIMMUNE   (United States)

^c PFIZER INC   (United States)

Author keywords

Backbone dynamics; Calorimetry (DSC); Excipients; Flexibility; Formulation; Hydrogen deuterium exchange; Mass spectrometry; Monoclonal antibody; Size exclusion chromatography; Stability

Indexed keywords

ARGININE; IMMUNOGLOBULIN G1; MONOMER; SUCROSE;

ARTICLE; CONTROLLED STUDY; DEUTERIUM HYDROGEN EXCHANGE; DIFFERENTIAL SCANNING CALORIMETRY; GEL PERMEATION CHROMATOGRAPHY; HEAVY CHAIN; IMMUNOGLOBULIN AGGREGATE; IMMUNOGLOBULIN STRUCTURE; MASS SPECTROMETRY; PH; PROTEIN STABILITY;

EID: 84879009285     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23543     Document Type: Article

References (92)

1. Wang W, Singh S, Zeng DL, King K, Nema S. 2007. Antibody structure, instability, and formulation. J Pharm Sci 96(1):1-26.
2. Kessler H, Mronga S, Muller G, Moroder L, Huber R. 1991. Conformational analysis of a IgG1 hinge peptide derivative in solution determined by NMR spectroscopy and refined by restrained molecular dynamics simulations. Biopolymers 31(10):1189-1204.
3. Hanson DC, Yguerabide J, Schumaker VN. 1981. Segmental flexibility of immunoglobulin G antibody molecules in solution: A new interpretation. Biochemistry 20(24):6842-6852.
4. Kim H, Matsunaga C, Yoshino A, Kato K, Arata Y. 1994. Dynamical structure of the hinge region of immunoglobulin G as studied by 13C nuclear magnetic resonance spectroscopy. J Mol Biol 236(1):300-309.
5. Boehm MK, Woof JM, Kerr MA, Perkins SJ. 1999. The Fab and Fc fragments of IgA1 exhibit a different arrangement from that in IgG: A study by X-ray and neutron solution scattering and homology modelling. J Mol Biol 286(5):1421-1447.
6. Kamerzell TJ, Esfandiary R, Joshi SB, Middaugh CR, Volkin DB. 2011. Protein-excipient interactions: Mechanisms and biophysical characterization applied to protein formulation development. Adv Drug Deliv Rev 63(13):1118-1159.
7. Cheng W, Joshi SB, He F, Brems DN, He B, Kerwin BA, Volkin DB, Middaugh CR. 2012. Comparison of high-throughput biophysical methods to identify stabilizing excipients for a model IgG2 monoclonal antibody: Conformational stability and kinetic aggregation measurements. J Pharm Sci 101(5):1701-1720.
8. Cordes AA, Carpenter JF, Randolph TW. 2012. Accelerated stability studies of abatacept formulations: Comparison of freeze-thawing- and agitation-induced stresses. J Pharm Sci 101(7):2307-2315.
9. Gibson TJ, McCarty K, McFadyen IJ, Cash E, Dalmonte P, Hinds KD, Dinerman AA, Alvarez JC, Volkin DB. 2011. Application of a high-throughput screening procedure with PEG-induced precipitation to compare relative protein solubility during formulation development with IgG1 monoclonal antibodies. J Pharm Sci 100(3):1009-1021.
10. Goldberg DS, Bishop SM, Shah AU, Sathish HA. 2010. Formulation development of therapeutic monoclonal antibodies using high-throughput fluorescence and static light scattering techniques: Role of conformational and colloidal stability. J Pharm Sci 100(4):1306-1315.
11. He F, Hogan S, Latypov RF, Narhi LO, Razinkov VI. 2010. High throughput thermostability screening of monoclonal antibody formulations. J Pharm Sci 99(4):1707-1720.
12. He F, Phan DH, Hogan S, Bailey R, Becker GW, Narhi LO, Razinkov VI. 2010. Detection of IgG aggregation by a high throughput method based on extrinsic fluorescence. J Pharm Sci 99(6):2598-2608.
13. Thakkar SV, Joshi SB, Jones ME, Sathish HA, Bishop SM, Volkin DB, Middaugh CR. 2012. Excipients differentially influence the conformational stability and pretransition dynamics of two IgG1 monoclonal antibodies. J Pharm Sci 101(9):3062-3077.
14. Thakkar SV, Kim JH, Samra HS, Sathish HA, Bishop SM, Joshi SB, Volkin DB, Middaugh CR. 2012. Local dynamics and their alteration by excipients modulate the global conformational stability of an lgG1 monoclonal antibody. J Pharm Sci 101(12):4444-4457.
15. Akers MJ. 2002. Excipient-drug interactions in parenteral formulations. J Pharm Sci 91(11):2283-2300.
16. Ohtake S, Kita Y, Arakawa T. 2011. Interactions of formulation excipients with proteins in solution and in the dried state. Adv Drug Deliv Rev 63(13):1053-1073.
17. Parkins DA, Lashmar UT. 2000. The formulation of biopharmaceutical products. Pharm Sci Technol Today 3(4):129-137.
18. Cuneo MJ, Tian Y, Allert M, Hellinga HW. 2008. The backbone structure of the thermophilic Thermoanaerobacter tengcongensis ribose binding protein is essentially identical to its mesophilic E. coli homolog. BMC Struct Biol 8(20).
19. Feng XL, Zhao X, Yu H, Sun TD, Huang XR. 2012. Molecular dynamics simulations of the thermal stability of tteRBP and ecRBP. J Biomol Struct Dyn 1-15
20. Leone M, Di Lello P, Ohlenschlager O, Pedone EM, Bartolucci S, Rossi M, Di Blasio B, Pedone C, Saviano M, Isernia C, Fattorusso R. 2004. Solution structure and backbone dynamics of the K18G/R82E Alicyclobacillus acidocaldarius thioredoxin mutant: A molecular analysis of its reduced thermal stability. Biochemistry 43(20):6043-6058.
21. Kamerzell TJ, Ramsey JD, Middaugh CR. 2008. Immunoglobulin dynamics, conformational fluctuations, and nonlinear elasticity and their effects on stability. J Phys Chem B 112(10):3240-3250.
22. Kamerzell TJ, Middaugh CR. 2008. The complex inter-relationships between protein flexibility and stability. J Pharm Sci 97(9):3494-3517.
23. Kamerzell TJ, Middaugh CR. 2007. Two-dimensional correlation spectroscopy reveals coupled immunoglobulin regions of differential flexibility that influence stability. Biochemistry 46(34):9762-9773.
24. Kamerzell TJ, Unruh JR, Johnson CK, Middaugh CR. 2006. Conformational flexibility, hydration and state parameter fluctuations of fibroblast growth factor-10: Effects of ligand binding. Biochemistry 45(51):15288-15300.
25. Ramsey JD, Gill ML, Kamerzell TJ, Price ES, Joshi SB, Bishop SM, Oliver CN, Middaugh CR. 2009. Using empirical phase diagrams to understand the role of intramolecular dynamics in immunoglobulin G stability. J Pharm Sci 98(7):2432-2447.
26. Engen JR. 2009. Analysis of protein conformation and dynamics by hydrogen/deuterium exchange MS. Anal Chem 81(19):7870-7875.
27. Kaltashov IA, Bobst CE, Abzalimov RR, Wang G, Baykal B, Wang S. 2011. Advances and challenges in analytical characterization of biotechnology products: Mass spectrometry-based approaches to study properties and behavior of protein therapeutics. Biotechnol Adv 30(1):210-222.
28. Konermann L, Tong X, Pan Y. 2008. Protein structure and dynamics studied by mass spectrometry: H/D exchange, hydroxyl radical labeling, and related approaches. J Mass Spectrom 43(8):1021-1036.
29. Zhang A, Qi W, Singh SK, Fernandez EJ. 2011. A new approach to explore the impact of freeze-thaw cycling on protein structure: Hydrogen/deuterium exchange mass spectrometry (HX-MS). Pharm Res 28(5):1179-1193.
30. Zhang A, Singh SK, Shirts MR, Kumar S, Fernandez EJ. 2012. Distinct aggregation mechanisms of monoclonal antibody under thermal and freeze-thaw stresses revealed by hydrogen exchange. Pharm Res 29(1):236-250.
31. Houde D, Arndt J, Domeier W, Berkowitz S, Engen JR. 2009. Characterization of IgG1 conformation and conformational dynamics by hydrogen/deuterium exchange mass spectrometry. Anal Chem 81(7):2644-2651.
32. Houde D, Berkowitz SA, Engen JR. 2011. The utility of hydrogen/deuterium exchange mass spectrometry in biopharmaceutical comparability studies. J Pharm Sci 100(6):2071-2086.
33. Burkitt W, Domann P, O'Connor G. 2010. Conformational changes in oxidatively stressed monoclonal antibodies studied by hydrogen exchange mass spectrometry. Protein Sci 19(4):826-835.
34. Tang L, Sundaram S, Zhang J, Carlson P, Matathia A, Parekh B, Zhou Q, Hsieh MC. 2013. Conformational characterization of the charge variants of a human IgG1 monoclonal antibody using H/D exchange mass spectrometry. mAbs 5(1):114-125.
35. Li Y, Williams TD, Schowen RL, Topp EM. 2007. Characterizing protein structure in amorphous solids using hydrogen/deuterium exchange with mass spectrometry. Anal Biochem 366(1):18-28.
36. Li Y, Williams TD, Topp EM. 2008. Effects of excipients on protein conformation in lyophilized solids by hydrogen/deuterium exchange mass spectrometry. Pharm Res 25(2):259-267.
37. Sinha S, Li Y, Williams TD, Topp EM. 2008. Protein conformation in amorphous solids by FTIR and by hydrogen/deuterium exchange with mass spectrometry. Biophys J 95(12):5951-5961.
38. Bond MD, Panek ME, Zhang Z, Wang D, Mehndiratta P, Zhao H, Gunton K, Ni A, Nedved ML, Burman S, Volkin DB. 2010. Evaluation of a dual-wavelength size exclusion HPLC method with improved sensitivity to detect protein aggregates and its use to better characterize degradation pathways of an IgG1 monoclonal antibody. J Pharm Sci 99(6):2582-2597.
39. Barnard JG, Singh S, Randolph TW, Carpenter JF. 2011. Subvisible particle counting provides a sensitive method of detecting and quantifying aggregation of monoclonal antibody caused by freeze-thawing: Insights into the roles of particles in the protein aggregation pathway. J Pharm Sci 100(2):492-503.
40. Majumdar R, Manikwar P, Hickey JM, Arora J, Middaugh CR, Volkin DB, Weis DD. 2012. Minimizing carry-over in an online pepsin digestion system used for the H/D exchange mass spectrometric analysis of an IgG1 monoclonal antibody. J Am Soc Mass Spectrom 23(12):2140-2148.
41. Majumdar R, Manikwar P, Hickey JM, Samra HS, Sathish HA, Bishop SM, Middaugh CR, Volkin DB, Weis DD. 2013. Effect of salts from Hofmeister series on conformational stability, aggregation propensity and local flexibility of an IgG1 monoclonal antibody. Biochemistry, accepted manuscript.
42. Saphire EO, Parren PW, Pantophlet R, Zwick MB, Morris GM, Rudd PM, Dwek RA, Stanfield RL, Burton DR, Wilson IA. 2001. Crystal structure of a neutralizing human IGG against HIV-1: A template for vaccine design. Science 293(5532):1155-1159.
43. Chennamsetty N, Voynov V, Kayser V, Helk B, Trout BL. 2009. Design of therapeutic proteins with enhanced stability. Proc Natl Acad Sci USA 106(29):11937-11942.
44. Ionescu RM, Vlasak J, Price C, Kirchmeier M. 2008. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. J Pharm Sci 97(4):1414-1426.
45. Freire E. 1995. Differential scanning calorimetry. Methods Mol Biol 40:191-218.
46. Li CH, Narhi LO, Wen J, Dimitrova M, Wen ZQ, Li J, Pollastrini J, Nguyen XC, Tsuruda T, Jiang Y. 2012. The effect of pH, temperature and salt on the stability of E. coli and CHO derived IgG1 Fc. Biochemistry 51(50):10056-10065.
47. Vermeer AW, Norde W. 2000. The thermal stability of immunoglobulin: Unfolding and aggregation of a multi-domain protein. Biophys J 78(1):394-404.
48. Welfle K, Misselwitz R, Hausdorf G, Hohne W, Welfle H. 1999. Conformation, pH-induced conformational changes, and thermal unfolding of anti-p24 (HIV-1) monoclonal antibody CB4-1 and its Fab and Fc fragments. Biochim Biophys Acta 1431(1):120-131.
49. Gabrielson JP, Brader ML, Pekar AH, Mathis KB, Winter G, Carpenter JF, Randolph TW. 2007. Quantitation of aggregate levels in a recombinant humanized monoclonal antibody formulation by size-exclusion chromatography, asymmetrical flow field flow fractionation, and sedimentation velocity. J Pharm Sci 96(2):268-279.
50. Rosenberg AS. 2006. Effects of protein aggregates: An immunologic perspective. AAPS J 8(3):E501-507.
51. Wang W, Singh SK, Li N, Toler MR, King KR, Nema S. 2012. Immunogenicity of protein aggregates-concerns and realities. Int J Pharm 431(1-2):1-11.
52. Chirmule N, Jawa V, Meibohm B. 2012. Immunogenicity to therapeutic proteins: Impact on PK/PD and efficacy. AAPS J 14(2):296-302.
53. Hawe A, Kasper JC, Friess W, Jiskoot W. 2009. Structural properties of monoclonal antibody aggregates induced by freeze-thawing and thermal stress. Eur J Pharm Sci 38(2):79-87.
54. Kumru OS, Liu J, Ji JA, Cheng W, Wang YJ, Wang T, Joshi SB, Middaugh CR, Volkin DB. 2012. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags. J Pharm Sci 101(10):3636-3650.
55. Hvidt A, Linderstrom-Lang K. 1954. Exchange of hydrogen atoms in insulin with deuterium atoms in aqueous solutions. Biochim Biophys Acta 14(4):574-575.
56. Hvidt A, Nielsen SO. 1966. Hydrogen exchange in proteins. Adv Protein Chem 21:287-386.
57. Wang A, Robertson AD, Bolen DW. 1995. Effects of a naturally occurring compatible osmolyte on the internal dynamics of ribonuclease A. Biochemistry 34(46):15096-15104.
58. Hutcheon GA, Parker MC, Moore BD. 2000. Measuring enzyme motility in organic media using novel H-D exchange methodology. Biotechnol Bioeng 70(3):262-269.
59. Lim WK, Rosgen J, Englander SW. 2009. Urea, but not guanidinium, destabilizes proteins by forming hydrogen bonds to the peptide group. Proc Natl Acad Sci USA 106(8):2595-2600.
60. Kim PS, Baldwin RL. 1982. Influence of charge on the rate of amide proton exchange. Biochemistry 21(1):1-5.
61. Rohl CA, Baldwin RL. 1997. Comparison of NH exchange and circular dichroism as techniques for measuring the parameters of the helix-coil transition in peptides. Biochemistry 36(28):8435-8442.
62. Bai Y, Milne JS, Mayne L, Englander SW. 1993. Primary structure effects on peptide group hydrogen exchange. Proteins 17(1):75-86.
63. Abbas SA, Sharma VK, Patapoff TW, Kalonia DS. 2012. Opposite effects of polyols on antibody aggregation: Thermal versus mechanical stresses. Pharm Res 29(3):683-694.
64. Banks DD, Latypov RF, Ketchem RR, Woodard J, Scavezze JL, Siska CC, Razinkov VI. 2012. Native-state solubility and transfer free energy as predictive tools for selecting excipients to include in protein formulation development studies. J Pharm Sci 101(8):2720-2732.
65. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. 1998. A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl Acad Sci USA 95(24):14142-14146.
66. Khan RH, Shabnum MS. 2001. Effect of sugars on rabbit serum albumin stability and induction of secondary structure. Biochemistry (Mosc) 66(9):1042-1046.
67. Kim YS, Jones LS, Dong A, Kendrick BS, Chang BS, Manning MC, Randolph TW, Carpenter JF. 2003. Effects of sucrose on conformational equilibria and fluctuations within the native-state ensemble of proteins. Protein Sci 12(6):1252-1261.
68. Lee JC, Timasheff SN. 1981. The stabilization of proteins by sucrose. J Biol Chem 256(14):7193-7201.
69. Kendrick BS, Chang BS, Arakawa T, Peterson B, Randolph TW, Manning MC, Carpenter JF. 1997. Preferential exclusion of sucrose from recombinant interleukin-1 receptor antagonist: Role in restricted conformational mobility and compaction of native state. Proc Natl Acad Sci USA 94(22):11917-11922.
70. Arakawa T, Timasheff SN. 1982. Stabilization of protein structure by sugars. Biochemistry 21(25):6536-6544.
71. Dudgeon K, Rouet R, Kokmeijer I, Schofield P, Stolp J, Langley D, Stock D, Christ D. 2012. General strategy for the generation of human antibody variable domains with increased aggregation resistance. Proc Natl Acad Sci USA 109(27):10879-10884.
72. DePaz RA, Barnett CC, Dale DA, Carpenter JF, Gaertner AL, Randolph TW. 2000. The excluding effects of sucrose on a protein chemical degradation pathway: Methionine oxidation in subtilisin. Arch Biochem Biophys 384(1):123-132.
73. Barreca D, Laganà G, Ficarra S, Gattuso G, Magazù S, Torre R, Tellone E, Bellocco E. 2012. Spectroscopic determination of lysozyme conformational changes in the presence of trehalose and guanidine. Cell Biochem Biophys. 1-11.
74. Hodkinson JP, Radford SE, Ashcroft AE. 2012. The role of conformational flexibility in beta2-microglobulin amyloid fibril formation at neutral pH. Rapid Commun Mass Spectrom 26(16):1783-1792.
75. Lin TY, Timasheff SN. 1996. On the role of surface tension in the stabilization of globular proteins. Protein Sci 5(2):372-381.
76. Taneja S, Ahmad F. 1994. Increased thermal stability of proteins in the presence of amino acids. Biochem J 303(Pt 1):147-153.
77. Ito L, Shiraki K, Matsuura T, Okumura M, Hasegawa K, Baba S, Yamaguchi H, Kumasaka T. 2011. High-resolution X-ray analysis reveals binding of arginine to aromatic residues of lysozyme surface: Implication of suppression of protein aggregation by arginine. Protein Eng Des Sel 24(3):269-274.
78. Schneider CP, Trout BL. 2009. Investigation of cosolute-protein preferential interaction coefficients: New insight into the mechanism by which arginine inhibits aggregation. J Phys Chem B 113(7):2050-2058.
79. Shukla D, Trout BL. 2010. Interaction of arginine with proteins and the mechanism by which it inhibits aggregation. J Phys Chem B 114(42):13426-13438.
80. Arakawa T, Ejima D, Tsumoto K, Obeyama N, Tanaka Y, Kita Y, Timasheff SN. 2007. Suppression of protein interactions by arginine: A proposed mechanism of the arginine effects. Biophys Chem 127(1-2):1-8.
81. Shukla D, Trout BL. 2011. Preferential interaction coefficients of proteins in aqueous arginine solutions and their molecular origins. J Phys Chem B 115(5):1243-1253.
82. Lilyestrom WG, Shire SJ, Scherer TM. 2012. Influence of the cosolute environment on IgG solution structure analyzed by small-angle X-ray scattering. J Phys Chem B 116(32):9611-9618.
83. Houde D, Peng Y, Berkowitz SA, Engen JR. 2010. Post-translational modifications differentially affect IgG1 conformation and receptor binding. Mol Cell Proteomics 9(8):1716-1728.
84. Zhang J, Topp EM. 2012. Protein G, protein A and protein A-derived peptides inhibit the agitation induced aggregation of IgG. Mol Pharm 9(3):622-628.
85. Dimitrov DS. 2009. Engineered CH2 domains (nanoantibodies). mAbs 1(1):26-28.
86. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS. 2009. Engineered human antibody constant domains with increased stability. J Biol Chem 284(21):14203-14210.
87. Gasymov OK, Abduragimov AR, Glasgow BJ. 2011. The conserved disulfide bond of human tear lipocalin modulates conformation and lipid binding in a ligand selective manner. Biochim Biophys Acta 1814(5):671-683.
88. Yu XW, Tan NJ, Xiao R, Xu Y. 2012. Engineering a disulfide bond in the lid hinge region of Rhizopus chinensis lipase: Increased thermostability and altered acyl chain length specificity. PloS ONE 7(10):e46388.
89. Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS. 2011. Shortened engineered human antibody CH2 domains: Increased stability and binding to the human neonatal Fc receptor. J Biol Chem 286(31):27288-27293.
90. Arakawa T, Tsumoto K. 2003. The effects of arginine on refolding of aggregated proteins: Not facilitate refolding, but suppress aggregation. Biochem Biophys Res Commun 304(1):148-152.
91. Lange C, Rudolph R. 2009. Suppression of protein aggregation by l-arginine. Curr Pharm Biotechnol 10(4):408-414.
92. Shiraki K, Kudou M, Fujiwara S, Imanaka T, Takagi M. 2002. Biophysical effect of amino acids on the prevention of protein aggregation. J Biochem 132(4):591-595.